What is Zacks Research’s Forecast for Glaukos Q4 Earnings?

Glaukos Co. (NYSE:GKOS) – Investment analysts at Zacks Research lifted their Q4 2026 earnings estimates for shares of Glaukos in a research report issued on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings per share of $0.06 for the quarter, up from their previous forecast of $0.03. The consensus estimate for Glaukos’ current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos’ FY2027 earnings at $0.82 EPS.

Several other equities research analysts also recently issued reports on the stock. Piper Sandler restated an “overweight” rating and issued a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Stifel Nicolaus raised their price target on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, December 31st. Needham & Company LLC boosted their price objective on shares of Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and increased their target price for the company from $132.00 to $162.00 in a research note on Wednesday, December 11th. Finally, Morgan Stanley downgraded Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a research report on Monday, December 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $163.25.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $102.43 on Monday. Glaukos has a 12 month low of $85.04 and a 12 month high of $163.71. The company has a market cap of $5.79 billion, a P/E ratio of -35.69 and a beta of 0.99. The business’s 50 day moving average is $140.86 and its two-hundred day moving average is $137.69. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. IFP Advisors Inc bought a new position in Glaukos in the 4th quarter valued at $43,000. Asset Planning Inc acquired a new position in shares of Glaukos in the 4th quarter valued at $90,000. CoreCap Advisors LLC boosted its holdings in Glaukos by 36.4% during the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock worth $112,000 after buying an additional 200 shares during the last quarter. Harvest Fund Management Co. Ltd grew its holdings in Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares during the period. Finally, Picton Mahoney Asset Management acquired a new position in shares of Glaukos in the 4th quarter valued at $125,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Glaukos

In related news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $15,310,024.65. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,744 shares of company stock valued at $2,504,131. Corporate insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.